Biosimilars 2021 Year in Review
Fish & Richardson Trademark & Copyright Thoughts
JANUARY 11, 2022
The letter discusses the BPCIA and the Hatch-Waxman Act frameworks (for small molecule drugs) and sets forth several topics for USPTO’s consideration and further discussion: engagement between FDA and USPTO to increase efficiencies, possible misuse of the patent system (e.g.,
52 
Let's personalize your content